STUB1 and therapy-related myeloid neoplasm: In patients undergoing autologous stem cell transplantation for lymphoma, CHIP at the time of transplantation, particularly if PPMD1 was mutated, has been reportedly associated with inferior survival and increased risk of therapy-related myeloid neoplasm (TMN) in the form of AML and MDS [39].